A phase II study of buparlisib in relapsed or refractory thymomas

PURPOSE: To investigate the efficacy and safety of buparlisib, an oral pan-PI3K inhibitor, in relapsed or refractory thymomas. METHODS: This was a single center, single arm, open label phase II trial of buparlisib in patients with recurrent thymoma who have progressed after at least one prior line o...

Descripción completa

Detalles Bibliográficos
Autores principales: Abu Zaid, Mohammad I., Radovich, Milan, Althouse, Sandra, Liu, Hao, Spittler, Aaron J., Solzak, Jeffrey, Badve, Sunil, Loehrer, Patrick J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623263/
https://www.ncbi.nlm.nih.gov/pubmed/36330484
http://dx.doi.org/10.3389/fonc.2022.891383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623263/
https://www.ncbi.nlm.nih.gov/pubmed/36330484
http://dx.doi.org/10.3389/fonc.2022.891383

Ejemplares similares